Narrow your search

Library

FARO (12)

KU Leuven (12)

LUCA School of Arts (12)

Odisee (12)

Thomas More Kempen (12)

Thomas More Mechelen (12)

UCLL (12)

ULiège (12)

VIVES (12)

Vlaams Parlement (12)

More...

Resource type

book (32)


Language

English (30)

French (2)


Year
From To Submit

2022 (7)

2021 (5)

2020 (12)

2019 (3)

2018 (3)

More...
Listing 1 - 10 of 32 << page
of 4
>>
Sort by

Book
Renforcement de la lipogenèse : caractéristique métabolique des cellules cancéreuses : intérêt pharmacologique potentiel
Authors: --- ---
Year: 2011 Publisher: Bruxelles: UCL,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Lipogenesis (de novo fatty acid synthesis) is one of the metabolic changes needed for tumor evolution. This occurs in the major part à cancer cells. In those cells, some of the lipogenic enzyme are overexpressed. In this work, we focus on FAS: fatty acid synthase. FAS (multifunctional enzyme) is an oncogene, catalyzing fatty acid biosynthesis in the cytoplasm. When FAS is overexpressed, cancer prognostic is poor. It was observed for example for breast or prostatic cancer. That’s why inhibition (by pharmacological agents or genetic) appears as a new target therapy for establishment of antitmoral therapy. Consequently, apoptosis in cancer cells in induced and can be observed in vitro and in vivo. As far as we know, pharmalogical inhibitors of FAS have all that they could stop tumoral cell proliferation, cause their death (by apoptosis) and avoid tumoral growth. Normal cells, don’t suffer of the FAS inhibitors effects, because FAS isn’t’ overexpressed there. Among the know inhibitors of FAS, we can notice: cerulenin (poorly specific of lipogenesis), C75 (a derived compound from cerulenin, more specific, but inducing a loss of weight) and orlistat (medicine used for obesity treatment, that seems to be more specific). They are different by their inhibition mechanism and by their binding site. All of them proved their antitumoral potential despite their differences. Further researchers should be helpful which catalytic domain may be the most promising target for drug development based on FAS inhibition (chemotherapy as welle as chemoprevention). L’augmentation de la lipogenèse (ou synthèse d’acides gras de novo) fait partie des adaptations métaboliques indispensables à la croissance et à la survie tumorale. Ce renforcement de la lipogenèse est une caractéristique commune à de nombreuses cellules cancéreuses, mis en évidence par une augmentation élevée de l’expression des enzymes lipogéniques telles que le fatty acid synthase (FAS). Cette enzyme multifonctionnelle, constituant un oncogène, catalyse la biosynthèse des acides gras à longue chaîne dans le cytoplasme. Surexprimée dans la majorité des cancers et à un stade précoce pour certains d’entre eux ; elle annonce un mauvais pronostic notamment dans les cancers du sein et de la prostate. Ainsi, FAS apparaît comme une nouvelle cible de choix pour le développement de traitements antitumoraux. L’inhibition de FAS par des agents pharmacologiques ou par des moyens génétiques représente donc un réel intérêt. La synthèse d’acides gras de novo est essentielle à la progression tumorale, c’est pourquoi l’inhibition de la lipogenèse ciblant FAS entraîne l’apoptose sélective des cellules cancéreuses aussi bien in vitro qu’in vivo. Les inhibiteurs pharmacologiques de FAS identifiés jusqu’à maintenant, ont montré qu’ils pouvaient bloquer la prolifération des cellules tumorales, susciter leur mort et empêcher la croissance de la tumeur. Cet effet est minimisé chez les cellules saines puisque FAS n’y est pas surexprimée. Parmi les inhibiteurs de FAS connus, on réactive de la cérulénine (inhibiteur peu spécifique de la lipogenèse), C75 (forme moins réactive de la céruléline, plu spécifique, mais qui provoque une perte de poids) et l’orlistat (médicament utilisé dans le traitement de l’obésité, qui inhibe le domaine thioestérase de FAS et semble plus spécifique). Ils différent d’une part leur mécanisme d’inhibition, et d’autre part par le domaine catalytique qu’ils ciblent. Tous ont prouvé leur efficacité à induire des effets antitumoraux malgré ces différences. La poursuite des recherches devrait permettre de déterminer quel domaine catalytique de FAS constitue al cible la plus prometteuse pour le développement d’un médicament de chimioprévention anticancéreuse qui inhibe FAS.


Book
Metabolic Adaptation to Cell Growth and Proliferation in Normal and Pathological Conditions
Authors: ---
Year: 2018 Publisher: Frontiers Media SA

Loading...
Export citation

Choose an application

Bookmark

Abstract

Proliferating cells must adapt their metabolism to fulfill the increased requirements for energy demands and biosynthetic intermediates. This adaptation is particularly relevant in cancer, where sustained rapid proliferation combined with the harsh conditions of the tumor microenvironment represent a major metabolic challenge. Noteworthy, metabolic reprogramming is now considered one of the hallmarks of cancer. However, the one size fits all rarely applies to the metabolic rewiring occurring in cancer cells, which ultimately depends on the combination of several factors such as the tumor’s origin, the specific genetic alterations and the surrounding microenvironment. In the present Research Topic, we compile a series of articles that discuss different metabolic adaptations that proliferating cells undergo to sustain growth and division, as well as the potential therapeutic window to treat certain pathologies, with a special focus on cancer.


Book
Metabolic Adaptation to Cell Growth and Proliferation in Normal and Pathological Conditions
Authors: ---
Year: 2018 Publisher: Frontiers Media SA

Loading...
Export citation

Choose an application

Bookmark

Abstract

Proliferating cells must adapt their metabolism to fulfill the increased requirements for energy demands and biosynthetic intermediates. This adaptation is particularly relevant in cancer, where sustained rapid proliferation combined with the harsh conditions of the tumor microenvironment represent a major metabolic challenge. Noteworthy, metabolic reprogramming is now considered one of the hallmarks of cancer. However, the one size fits all rarely applies to the metabolic rewiring occurring in cancer cells, which ultimately depends on the combination of several factors such as the tumor’s origin, the specific genetic alterations and the surrounding microenvironment. In the present Research Topic, we compile a series of articles that discuss different metabolic adaptations that proliferating cells undergo to sustain growth and division, as well as the potential therapeutic window to treat certain pathologies, with a special focus on cancer.


Book
Metabolic Adaptation to Cell Growth and Proliferation in Normal and Pathological Conditions
Authors: ---
Year: 2018 Publisher: Frontiers Media SA

Loading...
Export citation

Choose an application

Bookmark

Abstract

Proliferating cells must adapt their metabolism to fulfill the increased requirements for energy demands and biosynthetic intermediates. This adaptation is particularly relevant in cancer, where sustained rapid proliferation combined with the harsh conditions of the tumor microenvironment represent a major metabolic challenge. Noteworthy, metabolic reprogramming is now considered one of the hallmarks of cancer. However, the one size fits all rarely applies to the metabolic rewiring occurring in cancer cells, which ultimately depends on the combination of several factors such as the tumor’s origin, the specific genetic alterations and the surrounding microenvironment. In the present Research Topic, we compile a series of articles that discuss different metabolic adaptations that proliferating cells undergo to sustain growth and division, as well as the potential therapeutic window to treat certain pathologies, with a special focus on cancer.


Book
Rôle de la PKB dans la stimulation de la lipogenèse par l'insuline
Authors: --- ---
Year: 2011 Publisher: Bruxelles: UCL,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Prevalence of obesity due to sedentary lifestyle and overeating is increasing in our society. Obesity leads to pathologies such as type 2 diabetes. Because of its high incidence in the world and its serious health problem, the mechanism leading to its development is an important study. Lipogenesis is the metabolic pathway for fatty acid synthesis and it is modulated by nutrients and hormones. In this study, we focused on insulin-stimulated lipogenesis in adipose tissue and especially in the implication of protein kinase B (PKB) metabolic pathway. To study the implication of PKB on fatty acid synthesis, we used a specific PKB inhibitor, Akti1/2 in adipocytes and adipose tissue incubations and adipose tissues of PKB knock-out mice. Previously in the laboratory, it was shown that Akti- 1/2 inhibits insulin-stimulated de novo lipogenesis with fructose as carbohydrate substrate. The inhibitory effect of Akti-1/2 on PKB activation and phosphorylation by insulin was verified by activity measurements and western blot (WB). The effect of Akti- 1/2 on insulin-induced changes in phosphorylation state of the lipogenic enzymes such as pyruvate dehydrogenase (PDH), ATP-citrate-lyase (ACL) and acetyl-CoA carboxylase (ACC) was studied. Our results showed that insulin stimulated ACC dephosphorylation was abolished by Akti-1/2. PKB is thus likely to be involved in insulin-induced ACC activation by dephosphorylation. Insulin-stimulated dephosphorylation and activation of PDH and increased ACL phosphorylation persisted in the presence of Akti-1/2. These results suggest that PKB is flot implicated in insulin-induced PDH activation by dephosphorylation or in the increased ACL phosphorylation at the S454 site. Le surpoids, dû à la sédentarité et à la suralimentation, est en augmentation constante dans notre société. L’obésité est responsable de nombreuses pathologies tel que le diabète de type 2. En raison de son incidence élevée et de ses graves conséquences, la compréhension des mécanismes régissant son développement est une étude importante. La lipogenèse est l’ensemble des voies anaboliques menant à la synthèse des acides gras. Elle fait l’objet de régulation alimentaire et hormonale. Dans ce travail, nous nous sommes intéressés à la stimulation de la lipogenèse par l’insuline et, plus particulièrement au rôle de la protéine kinase B (PKB) dans cet effet métabolique de l’insuline sur le tissu adipeux. Afin d’étudier l’implication de cette kinase sur la synthèse des acides gras, nous avons utilisé un inhibiteur de la PKB, l’Akti-1/2 dans les incubations d’adipocytes et de tissus adipeux. Les tissus adipeux de souris sauvages ou invalidées pour l’isoforme 3 de la PKB (KO PKBp) ont également été utilisés. Des études préliminaires au sein du laboratoire ont montré que l’Akti-1/2 inhibe la lipogenèse à partir du fructose comme substrat glucidique. L’inhibition de la PKB par l’Akti1/2 a été vérifiée par le dosage de son activité ainsi que par la mesure de son état de phosphorylation par western blot (WB). Nous avons ensuite évalué l’effet de l’Akti- 1/2 sur les changements induits par l’insuline sur l’état de phosphorylation des différentes enzymes impliquées dans la lipogenèse tels que la pyruvate déshydrogénase (PDH), l’ATP-citrate lyase (ACL) et l’acétyl-CoA carboxylase (ACC). Nos résultats montrent que la déphosphorylation de l’ACC induite par l’insuline est abolie par l’Akti- 1/2. L’activation par déphosphorylation de l’ACC stimulée par l’insuline implique probablement la PKB. L’activation par déphosphorylation de la PDH et l’augmentation de la phosphorylation de l’ACE induites par l’insuline persistent en présence d’Akti-l/2. Il semblerait que ni l’activation par déphosphorylation de la PDH, ni la phosphorylation de l’ACL induites par l’insuline, n’impliquent la PKB.


Book
Energy Metabolism and Diet
Authors: ---
Year: 2022 Publisher: Basel MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Energy metabolism at whole-body, cellular, and even organelle, i.e., mitochondrial, levels requires adequate regulation in order to maintain or improve (metabolic) health. In eukaryotic cells, mitochondria are key players in energy (ATP) production via oxidative phosphorylation. Both macro- and micronutrients potentially influence energy metabolism and mitochondrial functioning, either as substrates for (oxidative) catabolism or as essential constituents of enzymes or protein complexes involved in (mitochondrial) energy metabolism. This book contains a valuable collection of empirical preclinical and human studies to assist in the development of understanding and progress this area of research on improving health and, more specifically, metabolic health.


Book
Energy Metabolism and Diet
Authors: ---
Year: 2022 Publisher: Basel MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Energy metabolism at whole-body, cellular, and even organelle, i.e., mitochondrial, levels requires adequate regulation in order to maintain or improve (metabolic) health. In eukaryotic cells, mitochondria are key players in energy (ATP) production via oxidative phosphorylation. Both macro- and micronutrients potentially influence energy metabolism and mitochondrial functioning, either as substrates for (oxidative) catabolism or as essential constituents of enzymes or protein complexes involved in (mitochondrial) energy metabolism. This book contains a valuable collection of empirical preclinical and human studies to assist in the development of understanding and progress this area of research on improving health and, more specifically, metabolic health.


Book
Nutraceuticals: The New Frontier
Author:
Year: 2020 Publisher: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Well-being is received increased attention from people, researchers, and physicians. The main goal is to prevent the onset of pathologic health issues instead of using conventional pharmacological approaches unless absolutely necessary. Prevention and well-being are closely linked to the wrong lifestyle and dietary habits, which can determine the onset of illness. Some health conditions can be prevented and treated with the use of nutraceuticals in daily diet. Nutraceuticals are pharmacologically active substances that can be extracted from vegetable or animal products, and concentrated and administered in a suitable pharmaceutical form. A nutraceutical can provide beneficial health effects, e.g., the prevention and/or, in some cases, the treatment of disease. The key aspect is defining the range of possible uses for these new food-drugs and substantiation with in vitro and in vivo clinical data that support their efficacy, safety, and health benefits. This Special Issue is dedicated to assessing the sources, composition, formulation, use, experience in clinical use, mechanisms of action, and clinical data of nutraceuticals, which represent a new horizon for therapy and provide valuable tools to reduce the cost of the healthcare system, addressing resources for prevention rather than pharmacological therapy.


Book
Energy Metabolism and Diet
Authors: ---
Year: 2022 Publisher: Basel MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Energy metabolism at whole-body, cellular, and even organelle, i.e., mitochondrial, levels requires adequate regulation in order to maintain or improve (metabolic) health. In eukaryotic cells, mitochondria are key players in energy (ATP) production via oxidative phosphorylation. Both macro- and micronutrients potentially influence energy metabolism and mitochondrial functioning, either as substrates for (oxidative) catabolism or as essential constituents of enzymes or protein complexes involved in (mitochondrial) energy metabolism. This book contains a valuable collection of empirical preclinical and human studies to assist in the development of understanding and progress this area of research on improving health and, more specifically, metabolic health.


Book
Nutraceuticals: The New Frontier
Author:
Year: 2020 Publisher: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Well-being is received increased attention from people, researchers, and physicians. The main goal is to prevent the onset of pathologic health issues instead of using conventional pharmacological approaches unless absolutely necessary. Prevention and well-being are closely linked to the wrong lifestyle and dietary habits, which can determine the onset of illness. Some health conditions can be prevented and treated with the use of nutraceuticals in daily diet. Nutraceuticals are pharmacologically active substances that can be extracted from vegetable or animal products, and concentrated and administered in a suitable pharmaceutical form. A nutraceutical can provide beneficial health effects, e.g., the prevention and/or, in some cases, the treatment of disease. The key aspect is defining the range of possible uses for these new food-drugs and substantiation with in vitro and in vivo clinical data that support their efficacy, safety, and health benefits. This Special Issue is dedicated to assessing the sources, composition, formulation, use, experience in clinical use, mechanisms of action, and clinical data of nutraceuticals, which represent a new horizon for therapy and provide valuable tools to reduce the cost of the healthcare system, addressing resources for prevention rather than pharmacological therapy.

Listing 1 - 10 of 32 << page
of 4
>>
Sort by